Chargement en cours...
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006. Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase i...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi Publishing Corporation
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2712676/ https://ncbi.nlm.nih.gov/pubmed/19636423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/896407 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|